Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt’s lymphoma

Constant efforts are being made to develop methods for improving cancer immunotherapy, including cytokine-induced killer (CIK) cell therapy. Numerous heat shock protein (HSP) 90 inhibitors have been assessed for antitumor efficacy in preclinical and clinical trials, highlighting their individual pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Fangfang, Wang, Yulu, Sharma, Amit, Yang, Yu, Liu, Hongde, Essler, Markus, Jaehde, Ulrich, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419260/
https://www.ncbi.nlm.nih.gov/pubmed/37569852
http://dx.doi.org/10.3390/ijms241512476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419260/
https://www.ncbi.nlm.nih.gov/pubmed/37569852
http://dx.doi.org/10.3390/ijms241512476

Ejemplares similares